178 related articles for article (PubMed ID: 26495785)
1. IL-8-Positive Tumor-Infiltrating Inflammatory Cells Are a Novel Prognostic Marker in Pancreatic Ductal Adenocarcinoma Patients.
Fang Y; Saiyin H; Zhao X; Wu Y; Han X; Lou W
Pancreas; 2016; 45(5):671-8. PubMed ID: 26495785
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of elevated serum soluble CD40 ligand levels as a diagnostic and prognostic tumor marker for pancreatic ductal adenocarcinoma.
Chung HW; Lim JB
J Transl Med; 2014 Apr; 12():102. PubMed ID: 24745825
[TBL] [Abstract][Full Text] [Related]
3. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
[TBL] [Abstract][Full Text] [Related]
4. Clinical and prognostic significance of serum transforming growth factor-beta1 levels in patients with pancreatic ductal adenocarcinoma.
Zhao J; Liang Y; Yin Q; Liu S; Wang Q; Tang Y; Cao C
Braz J Med Biol Res; 2016 Jul; 49(8):. PubMed ID: 27464025
[TBL] [Abstract][Full Text] [Related]
5. Prognostic and diagnostic value of REG4 serum and tissue expression in pancreatic ductal adenocarcinoma.
Saukkonen K; Hagström J; Mustonen H; Lehtinen L; Carpen O; Andersson LC; Seppänen H; Haglund C
Tumour Biol; 2018 Mar; 40(3):1010428318761494. PubMed ID: 29542402
[TBL] [Abstract][Full Text] [Related]
6. Reg proteins promote acinar-to-ductal metaplasia and act as novel diagnostic and prognostic markers in pancreatic ductal adenocarcinoma.
Li Q; Wang H; Zogopoulos G; Shao Q; Dong K; Lv F; Nwilati K; Gui XY; Cuggia A; Liu JL; Gao ZH
Oncotarget; 2016 Nov; 7(47):77838-77853. PubMed ID: 27788482
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of miR-124 predicts poor prognosis in pancreatic ductal adenocarcinoma patients.
Sun B; Liu X; Gao Y; Li L; Dong Z
Br J Biomed Sci; 2016 Oct; 73(4):152-157. PubMed ID: 27922430
[TBL] [Abstract][Full Text] [Related]
8. Expression and prognosis value of SHP2 in patients with pancreatic ductal adenocarcinoma.
Zheng J; Huang S; Huang Y; Song L; Yin Y; Kong W; Chen X; Ouyang X
Tumour Biol; 2016 Jun; 37(6):7853-9. PubMed ID: 26695153
[TBL] [Abstract][Full Text] [Related]
9. CXCR4--A Prognostic and Clinicopathological Biomarker for Pancreatic Ductal Adenocarcinoma: A Meta-Analysis.
Krieg A; Riemer JC; Telan LA; Gabbert HE; Knoefel WT
PLoS One; 2015; 10(6):e0130192. PubMed ID: 26091099
[TBL] [Abstract][Full Text] [Related]
10. Serum high mobility group box-1 is a powerful diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma.
Chung HW; Lim JB; Jang S; Lee KJ; Park KH; Song SY
Cancer Sci; 2012 Sep; 103(9):1714-21. PubMed ID: 22703527
[TBL] [Abstract][Full Text] [Related]
11. Serum JAK/STAT profile is related to the IL expression but not with the outcome in pancreatic adenocarcinoma patients.
Petrusel L; Ilies M; Leucuta D; Rusu I; Seicean A; Iuga C; Seicean R
Cell Mol Biol (Noisy-le-grand); 2021 Nov; 67(3):107-112. PubMed ID: 34933726
[TBL] [Abstract][Full Text] [Related]
12. Cytoplasmic TRAIL-R1 is a positive prognostic marker in PDAC.
Gundlach JP; Hauser C; Schlegel FM; Böger C; Röder C; Röcken C; Becker T; Egberts JH; Kalthoff H; Trauzold A
BMC Cancer; 2018 Jul; 18(1):777. PubMed ID: 30064384
[TBL] [Abstract][Full Text] [Related]
13. PROX1 and β-catenin are prognostic markers in pancreatic ductal adenocarcinoma.
Saukkonen K; Hagström J; Mustonen H; Juuti A; Nordling S; Kallio P; Alitalo K; Seppänen H; Haglund C
BMC Cancer; 2016 Jul; 16():472. PubMed ID: 27411302
[TBL] [Abstract][Full Text] [Related]
14. Clinical implication of Sox9 and activated Akt expression in pancreatic ductal adenocarcinoma.
Xia S; Feng Z; Qi X; Yin Y; Jin J; Wu Y; Wu H; Feng Y; Tao M
Med Oncol; 2015 Jan; 32(1):358. PubMed ID: 25428381
[TBL] [Abstract][Full Text] [Related]
15. Low RASSF6 expression in pancreatic ductal adenocarcinoma is associated with poor survival.
Ye HL; Li DD; Lin Q; Zhou Y; Zhou QB; Zeng B; Fu ZQ; Gao WC; Liu YM; Chen RW; Li ZH; Chen RF
World J Gastroenterol; 2015 Jun; 21(21):6621-30. PubMed ID: 26074700
[TBL] [Abstract][Full Text] [Related]
16. High expression of interleukin-22 and its receptor predicts poor prognosis in pancreatic ductal adenocarcinoma.
Wen Z; Liao Q; Zhao J; Hu Y; You L; Lu Z; Jia C; Wei Y; Zhao Y
Ann Surg Oncol; 2014 Jan; 21(1):125-32. PubMed ID: 24132627
[TBL] [Abstract][Full Text] [Related]
17. AHNAK2 is a potential prognostic biomarker in patients with PDAC.
Lu D; Wang J; Shi X; Yue B; Hao J
Oncotarget; 2017 May; 8(19):31775-31784. PubMed ID: 28423668
[TBL] [Abstract][Full Text] [Related]
18. Glypican-3 and KRT19 are markers associating with metastasis and poor prognosis of pancreatic ductal adenocarcinoma.
Yao H; Yang Z; Liu Z; Miao X; Yang L; Li D; Zou Q; Yuan Y
Cancer Biomark; 2016; 17(4):397-404. PubMed ID: 27689616
[TBL] [Abstract][Full Text] [Related]
19. Inflammatory cytokines and angiogenic factors as potential biomarkers in South African pancreatic ductal adenocarcinoma patients: A preliminary report.
Yako YY; Brand M; Smith M; Kruger D
Pancreatology; 2017; 17(3):438-444. PubMed ID: 28377069
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical expression of NEDD9, E-cadherin and γ-catenin and their prognostic significance in pancreatic ductal adenocarcinoma (PDAC).
Radulović P; Krušlin B
Bosn J Basic Med Sci; 2018 Aug; 18(3):246-251. PubMed ID: 29924959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
